secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001104659-24-038925
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acura extends NDA acceptance date for LTX-03 and note maturity to June 30, 2024
-------------------------------------------------------------------------------

- Amendment #8 to License Agreement extends FDA NDA acceptance deadline for LTX-03 from March 31 to June 30, 2024.
- If NDA not accepted by June 30, AD Pharma may terminate and take ownership of LTX-03 IP.
- Amendment #2 to Promissory Note extends maturity to June 30, 2024; principal $5.4M at 5.25% interest.
- AD Pharma, which owns ~65% of Acura common stock, may terminate license agreement at any time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465924038925/0001104659-24-038925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465924038925/tm249762d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-038925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer